Top of the page.
Skip the menu to main contents.
Move to main menu.
Skip to main contents.
Main menu starts here.
Skip the main menu to current location in your website.
Current location in your website.
Skip to main contents.
Start main contents.

Anti-inflammatory Agents

 

Toyama Chemical also conducts research in the development of anti-inflammatory agents for diseases such as rheumatoid arthritis (RA) and osteoarthritis. These are more than 0.7 million patients with RA in Japan, and 6.5 million overseas. Recently, several new drugs show the strong efficacy in RA patients, but they have some important problems like serious adverse effects, and so on. Toyama Chemical collaborates with organizations in Japan and overseas for efficiency in development of new drugs.

Subjects of research

T-614

[Image]T-614

T-614(Igratimod) which was discovered by Toyama Chemical and jointly developed with Eisai, shows suppression of immunoglobulin and inflammatory cytokine production, and is classified as a disease modifying anti-rheumatic drug (DMARD).

In the clinical trials, T-614 treated patients showed improvement in various inflammatory parameters and immunity abnormality. T-614 improved the disease activity among patients who showed inadequate response to previous treatment with marketed DMARDs. Additionally T-614 demonstrated efficacy in RA patients regardless of the stage or severity of their disease. T-614 will be launched and marketed by Taisho Toyama Pharmaceutical and Eisai after approval.

T-5224

[Image]T-5224

T-5224, a transcription factor Activator Protein-1 (AP-1) inhibitor, has been discovered as a new pipeline for anti-rheumatic drugs. Prof. S. Shiozawa from Kobe University found that signal transduction through AP-1 may play an important role in the pathogenesis of joint destruction and osteoporosis in RA patients. DNA binding of AP-1 induces an increase in pro-inflammatory proteins, which contribute to the progression of inflammation and joint destruction in RA patients. Toyama Chemical explored AP-1 inhibitors on the basis of the three-dimensional structure of the AP-1-DNA binding site using computer aided drug designing (CADD) with Prof. S. Hirono from Kitasato University. The Japan Science and Technology Agency have adopted this project into the Contract Development Program. Toyama Chemical is also actively researching other possible applications for T-5224 in inflammatory diseases where AP-1 is involved.

[Image]T-5224

Related Information

Business Field

Main business fields that TOYAMA CHEMICAL concentrates.


Back to Top
Footer starts here.
Pages ends here.
Move to top of the page.